Compare MRT & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MRT | ACOG |
|---|---|---|
| Founded | 2018 | 2000 |
| Country | Turkey | Canada |
| Employees | N/A | N/A |
| Industry | Rental/Leasing Companies | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 172.4M | 193.6M |
| IPO Year | 2021 | 2024 |
| Metric | MRT | ACOG |
|---|---|---|
| Price | $1.98 | $8.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $3.58 | ★ $16.00 |
| AVG Volume (30 Days) | 52.4K | ★ 95.5K |
| Earning Date | 08-08-2018 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 41.58 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,220,275.00 |
| Revenue This Year | $72.36 | $139.22 |
| Revenue Next Year | $95.75 | $134.48 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.12 | $4.50 |
| 52 Week High | $2.75 | $10.14 |
| Indicator | MRT | ACOG |
|---|---|---|
| Relative Strength Index (RSI) | 50.95 | 45.06 |
| Support Level | $1.97 | $8.30 |
| Resistance Level | $2.24 | $9.04 |
| Average True Range (ATR) | 0.14 | 0.51 |
| MACD | -0.01 | -0.06 |
| Stochastic Oscillator | 39.44 | 31.25 |
Marti Technologies Inc is Turkiye's urban mobility platform, helping to solve the country's transportation needs through tech-enabled services powered by a single mobility super app. The Group aims to offer tech-enabled urban transportation services to consumers across Turkiye through three service offerings: ride-hailing, delivery, and two-wheeled electric vehicle services. The Group's ride-hailing service matches consumers with car, motorcycle, and taxi drivers. The Group's delivery service provides same-hour package delivery by leveraging the Group's existing network of car and motorcycle drivers and consumer base.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimers disease, for which there are limited or no treatment options. The Companies current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Companies commercial development program for ZUNVEYL is focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.